Effects of Repeated Cocaine Exposure and Withdrawal on Voluntary Ethanol Drinking, and the Expression of Glial Glutamate Transporters in Mesocorticolimbic System of P Rats
Overview
Molecular Biology
Neurology
Affiliations
Glutamatergic neurotransmission within the brain's reward circuits plays a major role in the reinforcing properties of both ethanol and cocaine. Glutamate homeostasis is regulated by several glutamate transporters, including glutamate transporter type 1 (GLT-1), cystine/glutamate transporter (xCT), and glutamate aspartate transporter (GLAST). Cocaine exposure has been shown to induce a dysregulation in glutamate homeostasis and a decrease in the expression of GLT-1 and xCT in the nucleus accumbens (NAc). In this study, alcohol preferring (P) rats were exposed to free-choice of ethanol (15% and 30%) and/or water for five weeks. On Week 6, rats were administered (i.p.) cocaine (10 and 20mg/kg) or saline for 12 consecutive days. This study tested two groups of rats: the first group was euthanized after seven days of repeated cocaine i.p. injection, and the second group was deprived from cocaine for five days and euthanized at Day 5 after cocaine withdrawal. Only repeated cocaine (20mg/kg, i.p.) exposure decreased ethanol intake from Day 3 through Day 8. Co-exposure of cocaine and ethanol decreased the relative mRNA expression and the expression of GLT-1 in the NAc but not in the medial prefrontal cortex (mPFC). Importantly, co-exposure of cocaine and ethanol decreased relative expression of xCT in the NAc but not in the mPFC. Our findings demonstrated that chronic cocaine exposure affects ethanol intake; and ethanol and cocaine co-abuse alters the expression of glial glutamate transporters.
Arab A, Alasmari F, Albaker A, Alhazmi H, Alameen A, Alagail N Int J Mol Sci. 2023; 24(21).
PMID: 37958641 PMC: 10648086. DOI: 10.3390/ijms242115657.
Khatri S, Ulangkaya H, Maher E, Sadek S, Hong M, Woodcox A Neuropharmacology. 2023; 242:109773.
PMID: 37865136 PMC: 10842432. DOI: 10.1016/j.neuropharm.2023.109773.
Strickland J, Hatton K, Hays L, Rayapati A, Lile J, Rush C Behav Pharmacol. 2023; 34(5):275-286.
PMID: 37403694 PMC: 10328554. DOI: 10.1097/FBP.0000000000000731.
Abulseoud O, Alasmari F, Hussein A, Sari Y Front Neurosci. 2022; 16:841036.
PMID: 35864981 PMC: 9294323. DOI: 10.3389/fnins.2022.841036.
Substance abuse and neurotransmission.
Davis S, Zhu J Adv Pharmacol. 2022; 93:403-441.
PMID: 35341573 PMC: 9759822. DOI: 10.1016/bs.apha.2021.10.007.